Compare Enbridge Inc (ENB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Enbridge Inc trades at $56.31 (market cap $121.39B), while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: Enbridge Inc pays a 5.01% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| ENB | XBI | |
|---|---|---|
Market Cap | $121.39B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.04 | $164.28 |
52-Week Low | $44.59 | $85.16 |
Enterprise Value | $202.19B | — |
Dividend Yield | 5.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $55.89, up 1.49% recently, with technical indicators showing a bullish trend. The company reported strong Q1 2026 earnings, beating estimates with $0.71 EPS, and maintains a robust dividend. Revenue grew to $65.19B in 2025, with net income of $7.49B, though valuation ratios like a P/E of 27.02 appear elevated relative to historical norms. Analyst sentiment is mixed with a 48% buy rating, while recent news highlights the company's $28B growth project pipeline and its positioning as a defensive, high-yield stock amid market volatility.
The outlook for ENB is balanced: growth projects and consistent cash flow support dividend sustainability, offering a defensive yield in uncertain markets. However, risks include high leverage, sensitivity to interest rates, and execution challenges on capital projects. The stock's current valuation may limit near-term upside, making it more suitable for income-focused investors rather than those seeking rapid growth.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
